The Latest News from Our Field

We curate a digest of the latest news in our field for advocates, policymakers, community coalitions and all who work toward shaping policies and practices to effectively prevent substance use and treat addiction. Sign up here to receive weekly updates straight to your inbox.

View our curated digest of the latest research news, including how Xylazine, an animal tranquilizer known on the street as "tranq," has become one of the most dangerous additions to the illicit drug supply, increasingly mixed into fentanyl. Yet despite how often it shows up in overdoses, almost nothing is known about what it does once it is inside the human body. A new study begins to fill that gap by measuring xylazine directly in the blood of overdose patients — and the finding is striking: the drug lingers far longer than expected, clearing much more slowly in people than animal research had predicted. That may help explain why these patients stay sedated so long, and it gives doctors and medical examiners something they've never had much of before: real numbers to work from.
HHS announced over $700 million in federal grants for addressing homelessness, mental health, and addiction, including $96 million for the new STREETS program and $612 million for existing behavioral health grant programs.
FDA's memo on its decision to authorize two flavored e-cigarettes is lacking research details and acknowledges that the products were not better at helping people quit smoking than tobacco-flavored products.
A STAT article reports that despite more widespread support in recent years, there has been a recent resurgence of hostility toward medications for addiction treatment among federal officials.
A SAMHSA-run study on alcohol as part the U.S. dietary guidelines update, which was never released by the administration, was published in a scientific journal. It found that there was no net health benefit from alcohol and that even moderate amounts carry risk.
View our curated digest of the latest research news, including a community-based study that looked at how much naloxone was handed out, how many people were started on buprenorphine, how many stayed on it for at least six months, and how often risky new opioid prescriptions were written. The standouts were the two buprenorphine measures: communities that got more people onto the medication, and especially those that kept people on it longer, saw lower overdose death rates. Naloxone distribution and risky prescribing, by contrast, showed no clear link to death rates in this analysis.
The administration released a proposal to overhaul the regulation for all federal grants and reclassified thousands of federal employees, raising concerns for scientists and health agencies.
The 2026 Pain in the Nation report shows continued declines in drug overdose deaths and alcohol-induced deaths in 2024, but continued investment in prevention is needed to sustain this progress.
View our curated digest of the latest research news, including an investigation that synthesized data from multiple authoritative sources and found no net protective health effect from low levels of alcohol consumption. Instead, alcohol-related risks of serious illness and premature death begin to rise at relatively low levels of drinking. Notably, for men, the lifetime risk of dying from an alcohol-related cause reaches one in twenty-five when consumption reaches fourteen drinks per week. The pattern of drinking also matters: consuming more than one drink per occasion is associated with progressively higher risks of injury and chronic conditions, including cardiovascular disease and cancer. The findings support guidance that current adult drinkers limit alcohol consumption to no more than one drink per day.
Ten new states joined the Certified Community Behavioral Health Clinic Medicaid Demonstration Program, providing sustainable funding to expand access to comprehensive mental health and addiction services.
While the federal government has long tracked data on the role of alcohol in car crashes, the data on crashes involving other drugs remains lacking.
CMS's new rule on implementing work requirements will make it difficult for patients to get needed exemptions and create more burden for clinicians and states.
View our curated digest of the latest research news, including how alcohol use disorder is linked to problems with memory, attention, decision-making, and motor control, but the brain pathways behind those impairments are not fully understood. Analyzing functional MRI and neuropsychological data, the findings suggest that AUD disrupts specific brain systems underlying spatial working memory, attention, and motor performance. By connecting brain-networks to cognitive and motor problems, the study strengthens our understanding of AUD as a disorder that affects the neural machinery of thinking and action.
The next article in STAT’s “The Deadliest Drug” series focuses on alcohol use during pregnancy, which started climbing a decade ago after precipitous declines in the last 50 years.
FDA issued warning letters to 8 retailers for selling tobacco products that imitate everyday products. At the same time, some FDA officials say they were blindsided by the agency's new guidance on flavored vaping products, and other health officials and members of Congress express skepticism of the move.
HHS issued a U.S. surgeon general’s advisory on the harms of screen use. It outlines potential harms to young people and provides recommendations for youth, families, schools, health care providers, researchers, policymakers, and technology companies.
View our curated digest of the latest research news, including a study which found that combining buprenorphine with talk therapy made people more than five times as likely to reach remission within a year compared to those getting no treatment. Medication alone and therapy alone each roughly doubled the odds. The combination was clearly better than either piece by itself. This analysis provides national-scale evidence from over one hundred healthcare systems.
View our curated digest of the latest research news, including a study comparing single-step versus multi-step intranasal naloxone devices that found simpler naloxone delivery systems dramatically improved overdose response performance among individuals at risk for witnessing or experiencing an opioid overdose The findings suggest that device design itself may strongly influence the effectiveness of community and emergency department naloxone distribution programs, particularly in settings where formal training is limited.
FDA issued new guidance stating that it does not intend to prioritize enforcement against many e-cigarettes and nicotine pouches marketed without FDA authorization.
STAT launched a new investigative series, The Deadliest Drug, on the toll of alcohol and lack of adequate response.
Preliminary CDC data shows that about 70,000 Americans died of drug overdoses in 2025, about 14% fewer than the previous year.
New potent synthetic opioids called orphines, including cyclorphine, have been increasing in the illicit drug supply.
View our curated digest of the latest research news, including a study that examined whether negative experiences from drinking discourage future alcohol use as young people grow up. Among adolescents, bad experiences from alcohol did not strongly shape negative views about drinking, although having more negative expectations about alcohol was linked to lower alcohol use. In young adulthood, harmful drinking experiences increased negative beliefs about alcohol, but those beliefs did not appear to reduce drinking behavior. Negative experiences may help shape attitudes toward alcohol later in development, but those attitudes become less effective at preventing drinking as alcohol use becomes more established.
The National Drug Control Strategy outlines the government's approach to addressing substance use, including both interdiction and supply-side efforts and health-focused prevention, treatment, and recovery efforts.
FDA approved fruit-flavored vaping products for the first time, authorizing the sale of Glas blueberry and mango vaping pods, as well as two menthol-flavored products.
1 2 3 60